Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

by Harrison, Odile B. , Harris, Simon , MacLennan, Calman A. , Gulati, Sunita , Freixeiro, Paula , Sánchez-Busó, Leonor , Linder, Aline , Rollier, Christine S. , Unemo, Magnus , Dold, Christina , Ram, Sanjay , Corander, Jukka , Lewis, Lisa A.

in 631/250 / 631/326 / 692/699 / Aluminum / Antibodies / Antigens / Bacteria / Biomedical and Life Sciences / Biomedicine / Detergents / Drug resistance / FDA approval / Gonorrhea / Gram-negative bacteria / Infections / Infectious Diseases / Lipids / Medical Microbiology / Pathogens / Phylogenetics / Proteins / Public Health / Sexually transmitted diseases / STD / Vaccine / Vaccines / Virology

2026

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

2026

Confirm

Do you wish to request the book?

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

2026

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

Harrison, Odile B.,

Harris, Simon,

MacLennan, Calman A.,

Gulati, Sunita,

Freixeiro, Paula,

Sánchez-Busó, Leonor,

Linder, Aline,

Rollier, Christine S.,

Unemo, Magnus,

Dold, Christina,

Ram, Sanjay,

Corander, Jukka,

Lewis, Lisa A.

2026

Overview

Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31–59% effectiveness. We hypothesised that gonococcal OMV-based vaccines would have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560 lpxL1 − rmp − and FA1090 lpxL1 − rmp − induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254 lpxL1 − rmp − nOMV ( P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio

Subject

631/250

/ 631/326

/ 692/699